Neurotechnology company Paradromics will test its device in a trial aimed at safely restoring speech for people with severe motor impairments.
Category: biotech/medical – Page 19
Neuralink’s first patient says Elon Musk’s implant helped him “find purpose again”
The first recipient of the Neuralink implant has successfully turned the X comment section wholesome after posting how the implant gave him a newfound sense of purpose.
Shrinking materials hold big potential for smart devices, researchers say
Wearable electronics could be more wearable, according to a research team at Penn State. The researchers have developed a scalable, versatile approach to designing and fabricating wireless, internet-enabled electronic systems that can better adapt to 3D surfaces, like the human body or common household items, paving the path for more precise health monitoring or household automation, such as a smart recliner that can monitor and correct poor sitting habits to improve circulation and prevent long-term problems.
The method, detailed in Science Advances, involves printing liquid metal patterns onto heat-shrinkable polymer substrates—otherwise known as the common childhood craft “Shrinky Dinks.” According to team lead Huanyu “Larry” Cheng, James L. Henderson, Jr. Memorial Associate Professor of Engineering Science and Mechanics in the College of Engineering, the potentially low-cost way to create customizable, shape-conforming electronics that can connect to the internet could make the broad applications of such devices more accessible.
“We see significant potential for this approach in biomedical uses or wearable technologies,” Cheng said, noting that the field is projected to reach $186.14 billion by 2030. “However, one significant barrier for the sector is finding a way to manufacture an easy-to-customize device that can be applied to freestanding, freeform surfaces and communicate wirelessly. Our method solves that.”
Year-round edamame: Hydroponic LED plant factories redefine sustainable cultivation
Artificial light-type plant factories are an emerging agricultural innovation that enables crops to be grown year-round in precisely controlled environments. By adjusting factors such as light, temperature, humidity, carbon dioxide concentration, and nutrient delivery, these facilities can produce stable yields independent of climate conditions. They offer a promising way to reduce pesticide use and minimize the impacts of climate change.
However, legumes like edamame have long been considered difficult to cultivate in such settings because of their long growth periods, short storage periods, complex flowering, and pod-setting processes.
Against this backdrop, the research group, led by Professor Toshio Sano from the Faculty of Bioscience and Applied Chemistry, Hosei University, Japan, and Associate Professor Wataru Yamori of the Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan, had previously gained attention for successfully cultivating tomatoes under LED lighting in a plant factory.
3D imaging uncovers mosquito’s specialized neurons for detecting carbon dioxide
It’s bound to happen at a summer picnic, a peaceful walk in the woods or simply sitting in your backyard… a mosquito targets your blood for its next meal. You’ve been bitten. But how do mosquitoes find you?
Among several methods used to locate new hosts for blood-sucking, mosquitoes feature a keen ability to detect carbon dioxide. As we breathe out, we emit CO2 into the air around us, which mosquitoes can sense. But how?
Scientists have been aware of the mosquito’s ability to detect our carbon dioxide expirations but the intricate underlying physiological structures enabling these capabilities have largely remained unclear.
How glioblastoma tumors dodge chemotherapy
Glioblastoma is one of the deadliest brain cancers, with a median survival rate of just 15 months. Despite surgery and chemotherapy, more than 1250 clinical trials over the past 20 years have struggled to improve survival rates.
Published in Nature Communications, the study shows that a small population of drug-tolerant cells known as “persister cells” rewires its metabolism to survive chemotherapy, using an unexpected ally as an invisibility cloak: a fertility gene called PRDM9.
The authors identified that chemotherapy-induced PRDM9 upregulation promotes metabolic rewiring in glioblastoma stem cells, leading to chemotherapy tolerance. Mechanistically, PRDM9-dependent H3K4me3 at cholesterol biosynthesis genes enhances cholesterol biosynthesis, which persister cells rely on to maintain homeostasis under chemotherapy-induced oxidative stress and lipid peroxidation.
PRDM9 inhibition, combined with chemotherapy, results in strong anti-cancer efficacy in preclinical glioblastoma models, significantly enhancing the magnitude and duration of the antitumor response by eliminating persisters.
Previously, PRDM9 was only known as a fertility gene, active in reproductive cells at the very start of egg and sperm formation, long before fertilisation.
The researchers are now working with Australian biotech company Syntara to develop PRDM9 inhibitors for further testing in animal models, with the hope to eventually progress to human studies.
Targeting mitochondrial autophagy for anti-aging
Shan, W., Liu, Y., Tang, R. et al. Targeting mitochondrial autophagy for anti-aging. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02913-y.
Scientists map development of pancreas transport channels that deliver digestive enzymes
Organs often have fluid-filled spaces called lumens, which are crucial for organ function and serve as transport and delivery networks. Lumens in the pancreas form a complex ductal system, and its channels transport digestive enzymes to the small intestine. Understanding how this system forms in embryonic development is essential, both for normal organ formation and for diagnosing and treating pancreatic disorders.
Despite their importance, how lumens take certain shapes is not fully understood, as studies in other models have largely been limited to the formation of single, spherical lumens. Organoid models, which more closely mimic the physiological characteristics of real organs, can exhibit a range of lumen morphologies, such as complex networks of thin tubes.
Researchers in the group of Anne Grapin-Botton, director at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, and also Honorary Professor at TU Dresden, teamed up with colleagues from the group of Masaki Sano at the University of Tokyo (Japan), Tetsuya Hiraiwa at the Institute of Physics of Academia Sinica (Taiwan), and with Daniel Rivéline at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (France) to explore the processes involved in complex lumen formation.
Cancer Cells Paralyze Immune Cells
Immune cells work to fight infection and other diseases. Different subsets work together to elicit a healthy immune response; however, infections and disease can dysregulate cells and prevent effective immunity. Interestingly, cancer can use immune cells to its advantage.
Cancer employs various mechanisms to alter the immune system. Once established, tumor cells secrete proteins and molecules to generate a favorable environment. In this case, the tumor microenvironment (TME) becomes hypoxic due to a lack of oxygen with increased blood vessel growth to bring nutrients to the tumor and altered cell types that promote tumor progression. Specifically, tumor-secreted molecules polarize healthy immune cells, which allow cancer cells to proliferate and travel to distal tissues of the body.
T cells are specific immune cells responsible for identifying and targeting pathogens. Receptors on T cells recognize proteins on the surface of infected cells, which stimulate an immune response that eliminates the disease. These cells are critical for effective health and many immunotherapies aim to amplify or enhance T cell function. In the context of cancer, these T cells lose their function and, in some cases, promote tumor growth by inhibiting other immune cells. Unfortunately, treatment efficacy is limited to specific subsets of patients due to tumor type and stage of disease. Scientists are currently working to understand more about T cell biology and enhance immunotherapy.